Novo Nordisk's Factory Floor Becomes the Battleground as Buybacks Offset a 22% Slide
Published on 10/11/2026 at 12:31 | Editorial boerse-global.de
Novo Nordisk's manufacturing network has emerged as the pivotal variable in its near-term outlook, after U.S. regulators pushed back their review of the haemophilia A candidate Denecimig on October 2. The FDA tied the extension to ongoing remediation work at a production facility, while making clear it had found no deficiencies in the clinical efficacy or safety data. No fresh timeline for a final decision was attached.
The Danish drugmaker said the delay leaves its 2026 financial guidance untouched and continues to target a U.S. launch in the first half of 2027, provided approval comes through. Even so, the episode underscores how heavily the company's ambitions now rest on the operational readiness of its plants rather than on the strength of its science alone.
Pipeline Push Beyond the Core
Efforts to widen the clinical pipeline have continued in parallel. Roughly two weeks ago Novo Nordisk secured exclusive licensing rights to HRS-1596, an oral GLP-1/GIP candidate from Jiangsu Hengrui Pharmaceuticals. The deal carries a potential total value of up to USD 2.6 billion, including a USD 300 million upfront payment, and grants Novo Nordisk exclusive rights outside mainland China, Hong Kong, Macau and Taiwan. Since the agreement was struck, the share price has added 2.6%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Data presented at the annual meeting of the European Association for the Study of Diabetes (EASD) fleshed out the obesity story further. Patients switching from injectable GLP-1 therapies to the Wegovy pill shed an average of 4.0 kilograms over three months. Findings from the STEP-UP study pointed the same direction: among participants with elevated liver fat, 88.5% of those treated with injected Wegovy doses returned to normal fat levels below 5% by week 72. Separate results for the obesity candidate CagriSema showed a 22.4% weight reduction after 52 weeks, alongside a marked decline in fat tissue in the liver, pancreas and abdomen.
Buyback Momentum and a Cautious Street
Management has been leaning on share repurchases to counter the headwinds. By October 2, Novo Nordisk had bought back 36,604,179 B-shares since February 4, spending more than DKK 10.24 billion. The programme is capped at DKK 15 billion over a twelve-month window.
Sentiment, however, remains guarded. Citi Research trimmed its price target to DKK 296 from DKK 310 about two weeks ago, keeping a Neutral rating and pointing to limited prospects for margin growth through 2030. The stock's September 21 capital markets day offered little comfort either: according to Reuters, the shares gave up as much as 9% at one point as investors digested growth targets and the company's forthcoming patent expirations with restraint.
Ahead of the weekend the picture brightened slightly, with the stock closing Friday at EUR 34.40, up 1.3%. The year-to-date loss still stands at 22%. Investors get their next hard look at operating performance on November 4, 2026, when the company reports results for the first three quarters.
Ad
Novo Nordisk Stock: New Analysis - 11 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
